Related Experiment Videos
Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions
M D Ellison1, R J Krieg, J T Povlishock
1Department of Anatomy, Medical College of Virginia, Richmond 23298-0709.
Journal of Neuroimmunology
|August 1, 1990
Summary
Systemic recombinant human interleukin-2 (rIL-2) infusions temporarily increase cerebrovascular permeability to immunoglobulin G (IgG) in rats. Structural brain changes, including axonal degeneration, occur after single and multiple rIL-2 exposures.
Area of Science:
- Neuroscience
- Immunology
- Vascular Biology
Background:
- Recombinant human interleukin-2 (rIL-2) is used therapeutically.
- The impact of rIL-2 on the central nervous system, particularly cerebrovascular integrity, requires detailed investigation.
Purpose of the Study:
- To evaluate the effects of single and multiple systemic rIL-2 infusions on cerebrovascular permeability to immunoglobulin G (IgG) in a rat model.
- To examine ultrastructural changes in cerebral vasculature and brain parenchyma following rIL-2 administration.
Main Methods:
- Rats received single or multiple intravenous infusions of rIL-2.
- Cerebrovascular permeability to IgG was assessed at 6 and 24 hours post-infusion.
- Ultrastructural analysis of cerebral vasculature and brain parenchyma was performed.
Main Results:
- A single rIL-2 infusion moderately increased IgG permeability at 6 and 24 hours, which was not seen after 5 days of infusion.
- Cerebrovascular morphological alterations were observed as early as 6 hours after a single rIL-2 infusion.
- Structural changes, including axonal degeneration and demyelination, persisted and became more widespread with repeated rIL-2 infusions, affecting neuronal and glial cells.
Conclusions:
- Systemic rIL-2 can transiently disrupt the blood-brain barrier, increasing permeability to macromolecules like IgG.
- Repeated rIL-2 administration leads to persistent structural damage in the brain's vasculature and parenchyma.
- These findings highlight potential neurotoxic effects of rIL-2 therapy that warrant further investigation.